Header Logo

Connection

C OSBORNE to Lymphatic Metastasis

Back to Details
This is a "connection" page, showing publications C OSBORNE has written about Lymphatic Metastasis.
C OSBORNE
Connection Strength
0.583
Lymphatic Metastasis
  1. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol. 1999 Aug; 17(8):2334-40.
    View in: PubMed
    Score: 0.141
  2. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol. 2005 Sep 01; 23(25):5973-82.
    View in: PubMed
    Score: 0.053
  3. bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer. 1998 Apr 01; 82(7):1296-302.
    View in: PubMed
    Score: 0.032
  4. Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol. 1996 Jan; 14(1):46-51.
    View in: PubMed
    Score: 0.027
  5. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol. 1994 Oct; 12(10):2078-85.
    View in: PubMed
    Score: 0.025
  6. Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol. 1994 Mar; 12(3):467-74.
    View in: PubMed
    Score: 0.024
  7. One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study. J Clin Oncol. 1993 Sep; 11(9):1710-6.
    View in: PubMed
    Score: 0.023
  8. Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study. Breast Cancer Res Treat. 1992; 22(3):273-84.
    View in: PubMed
    Score: 0.021
  9. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009 Dec 19; 374(9707):2055-2063.
    View in: PubMed
    Score: 0.018
  10. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010 Jan; 11(1):55-65.
    View in: PubMed
    Score: 0.018
  11. Prognostic factors in breast cancer. Hematol Oncol Clin North Am. 1989 Dec; 3(4):641-52.
    View in: PubMed
    Score: 0.018
  12. Adjuvant therapy in node-negative breast cancer. A panel discussion. Breast Cancer Res Treat. 1989 Mar; 13(2):97-115.
    View in: PubMed
    Score: 0.017
  13. Adjuvant treatment of node-negative breast cancer. Tex Med. 1989 Jan; 85(1):32-6.
    View in: PubMed
    Score: 0.017
  14. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res. 2004 Nov 15; 10(22):7490-9.
    View in: PubMed
    Score: 0.013
  15. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003 Jul 03; 349(1):17-26.
    View in: PubMed
    Score: 0.012
  16. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study. Cancer. 2003 Jan 01; 97(1):21-9.
    View in: PubMed
    Score: 0.011
  17. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol. 1999 Oct; 17(10):3058-63.
    View in: PubMed
    Score: 0.009
  18. Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. J Natl Cancer Inst. 1999 Aug 18; 91(16):1391-7.
    View in: PubMed
    Score: 0.009
  19. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol. 1999 May; 17(5):1442-8.
    View in: PubMed
    Score: 0.009
  20. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study. J Clin Oncol. 1998 Jul; 16(7):2382-91.
    View in: PubMed
    Score: 0.008
  21. Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol. 1998 May; 16(5):1655-60.
    View in: PubMed
    Score: 0.008
  22. Telomerase activity and survival of patients with node-positive breast cancer. J Natl Cancer Inst. 1997 Dec 17; 89(24):1874-81.
    View in: PubMed
    Score: 0.008
  23. Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat. 1997 Apr; 43(2):153-63.
    View in: PubMed
    Score: 0.007
  24. Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. J Clin Oncol. 1996 Nov; 14(11):3009-17.
    View in: PubMed
    Score: 0.007
  25. The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res. 1996 Jul; 2(7):1199-206.
    View in: PubMed
    Score: 0.007
  26. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet. 1996 Apr 20; 347(9008):1066-71.
    View in: PubMed
    Score: 0.007
  27. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res. 1996 Mar; 2(3):585-92.
    View in: PubMed
    Score: 0.007
  28. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993 Feb 03; 85(3):200-6.
    View in: PubMed
    Score: 0.006
  29. Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: preliminary analysis of an intergroup study (INT 0076). J Natl Cancer Inst Monogr. 1992; (11):167-72.
    View in: PubMed
    Score: 0.005
  30. Chemotherapy versus observation in high-risk node-negative breast cancer patients. J Natl Cancer Inst Monogr. 1992; (11):97-104.
    View in: PubMed
    Score: 0.005
  31. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med. 1989 Feb 23; 320(8):485-90.
    View in: PubMed
    Score: 0.004
  32. Correlation of primary breast cancer histopathology and estrogen receptor content. Breast Cancer Res Treat. 1981; 1(1):37-41.
    View in: PubMed
    Score: 0.002
  33. Adjuvant therapy for stage II, estrogen receptor negative breast cancer. Breast Cancer Res Treat. 1981; 1(2):131-4.
    View in: PubMed
    Score: 0.002
  34. Extranodal presentation of non-Hodgkin's lymphomas in the testis. Cancer. 1976 Aug; 38(2):1026-35.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.